Saturday 17 October 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.7%, free cash flow fell 76.9% and total debt fell 88.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.23
0.01
−4.17%
Follow AEON
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.01% | 93.84% | 428.21% | 350.00% | |
| (0.05%) | (901.45%) | (536.00%) | (621.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.47% | 1,175.37% | (61,336.73%) | 1,693.21% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.14) | (1.74) | (0.30) | (0.27) | |
Free Cash Flow |
(13.23) | (17.31) | (12.03) | (13.64) | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(425.95%) | 99.37% | 134.21% | 114.35% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
4,405.67 | 0.44 | 0.20 | 0.25 | |
Depreciation/Fixed assets |
0.45 | 0.48 | 0.55 | 0.63 | |
Capex/Depreciation |
(0.16) | (0.05) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.14) | (1.74) | (0.30) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates